Sita Met Tablet Uses

Sita Met is a medication that combines two anti-diabetic drugs. It is primarily used to manage type 2 diabetes mellitus. The following are some common and off-label uses of the Sita-Met Tablet:

1. Type 2 Diabetes Mellitus: Sita Met is commonly used for the treatment of type 2 diabetes in adults. Type 2 diabetes is a chronic condition characterized by high blood sugar levels resulting from insulin resistance and inadequate insulin production.
2. Long-term Management: Sita Met is typically used for the long-term management of type 2 diabetes. It helps lower fasting and postprandial blood sugar levels, reduces HbA1c levels, and lowers the risk of complications associated with uncontrolled diabetes.

Off-label Uses of Sita Met Tablet

1. Polycystic Ovary Syndrome (PCOS): Sita Met may be used off-label to manage certain symptoms of PCOS, such as insulin resistance and elevated androgen levels.
2. Prediabetes: Prediabetes refers to a condition where blood sugar levels are higher than normal but not yet in the diabetic range. Sita Met may be considered off-label for individuals with prediabetes who are at high risk of developing type 2 diabetes.
3. Gestational Diabetes: Gestational diabetes occurs during pregnancy when blood sugar levels become elevated. In some cases, Sita Met may be used off-label to manage gestational diabetes. However, treatment decisions for gestational diabetes are typically individualized, and healthcare professionals will consider various factors before prescribing any medication.

Sita Met is one of the leading brands of Sitagliptin + Metformin, manufactured and marketed by (CCL) Consolidated Chemical Laboratories (Pvt) Ltd, Pakistan.

The following are some alternative brands of Sita Met and their manufacturers.

• Sitaglu Met : Hilton Pharmaceuticals (Pvt) Ltd, Pakistan.
• Treviamet : Getz Pharmaceuticals (Pvt) Ltd, Pakistan.
• Inosita-Plus : Pharmevo Pakistan (Pvt) Ltd.
• Gliptin Plus : Himont Pharmaceuticals (Pvt) Ltd, Pakistan.
• Duvel Plus : Martin Dow Pharma, Pakistan.
• Alosita-Met : Saffron Pharmaceuticals (Pvt) Ltd, Pakistan.
• Tagipmet : Highnoon Laboratories Ltd, Pakistan.
• Neoglip : Atco Laboratories (Pvt) Ltd, Pakistan.
• Sitagen-M : Ferozsons Laboratories Ltd, Pakistan.
• Gvia M : Genix Pharmaceuticals (Pvt) Ltd, Pakistan.

Presently, Sita Met is available in Tablet Form with the following Strengths.

Sita Met 50/500 Tablet: Sitagliptin 50mg + Metformin 500mg strengths.

Sita Met 50/1000 Tablet: Sitagliptin 50mg + Metformin 1000mg strengths.

Sita Met has certain contraindications, which are specific situations or conditions in which the use of Sita Met is not recommended due to potential risks.

Hypersensitivity or Allergy: Sita Met should not be used in individuals who have a known hypersensitivity or allergy to any components of the Sita Met.

Severe Kidney Dysfunction or Impairment: Sita Met is contraindicated in individuals with severe kidney dysfunction or impaired renal function. This includes conditions such as end-stage renal disease or an estimated glomerular filtration rate (eGFR) below the recommended threshold. Using Sita Met in these cases may increase the risk of lactic acidosis, a rare but serious condition.

Acute or Chronic Metabolic Acidosis: Sita Met is contraindicated in individuals with acute or chronic metabolic acidosis, as it may worsen the condition. Metabolic acidosis is characterized by an imbalance in the body’s acid-base levels, resulting in an excess of acid or a decrease in bicarbonate levels.

Diabetic Ketoacidosis: Sita Met should not be used for the treatment of diabetic ketoacidosis. Diabetic ketoacidosis is a serious complication of diabetes characterized by high blood sugar levels, ketone production, and acidosis. Insulin therapy and appropriate medical management are typically required for this condition.

Sita Met Dose for Treatment:

• One Tablet of 50/1000mg, once daily. This can be taken with or without food.

Sita Met Dose for Maintenance:

• One Tablet of 50/500mg,

The maximum recommended daily dose is four Tablets of Sita Met 50/500mg per day.

Sita Met’s mode of action depends on how its active ingredients work.

Sitagliptin Mode of Action:

• Sitagliptin (an active ingredient of Sita Met) is a dipeptidyl peptidase-4 (DPP-4) inhibitor. Its mode of action involves inhibiting the enzyme DPP-4, which is responsible for the breakdown of incretin hormones, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones play a crucial role in regulating blood sugar levels by stimulating insulin release from the pancreas and reducing the production of glucose by the liver. By inhibiting DPP-4, sitagliptin increases the levels of GLP-1 and GIP, resulting in enhanced insulin secretion and decreased glucagon release, ultimately leading to better glucose control.

Metformin Mode of Action:

• Metformin (another active ingredient of Sita Met) is a biguanide medication, it works by reducing the production of glucose by the liver. Metformin inhibits the enzyme involved in gluconeogenesis, the process by which the liver produces glucose. By suppressing excessive glucose production, metformin helps lower blood sugar levels.